Physician

Rumaisa Hameed, M.D

According to 2025 Medicare claims, Rumaisa Hameed, M.D (NPI: 1023447349) practices hematology/oncology in the Washington, DC-MD market, with the plurality of this provider's patient population coming from Prince Georges, MD. This provider's primary affiliated billing organization is MEDSTAR MEDICAL GROUP II LLC (NPI: 1184046187; TIN: 461322238) and primary practice location at 20735-3362. Hameed is affiliated with the Sound Physicians Long Term Care Management, LLC (ACO ID: A5220), participating under the MSSP model.

Hameed's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 341 traditional Medicare patients, billed 24,564 HCPCS/CPT codes, and received $401,826 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 422 prescription claims across 108 beneficiaries totaling $674,879 in drug costs, led by Sprycel (Dasatinib). 2021 DME data shows 24 claims. Open Payments data shows 3 records totaling $76. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $69,111 and ending at $401,826. Concurrently, Part D prescription costs have risen steadily, from $7,229 to $674,879. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $2,243 to $979.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	307	720	$69,111
2016	722	1,693	$151,708
2017	315	667	$61,861
2018	512	1,203	$94,520
2019	322	686	$52,423
2020	225	295	$31,475
2021	201	317	$25,795
2022	179	8,179	$61,526
2023	281	5,333	$134,552
2024	341	24,564	$401,826

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	55	116	$7,229
2016	147	376	$17,595
2017	61	162	$9,837
2018	39	92	$4,583
2019	31	68	$2,476
2020	36	65	$5,351
2021	37	64	$6,783
2022	17	34	$1,936
2023	64	155	$244,996
2024	108	422	$674,879

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	22	$1,074
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	12	$224
2020	N/R	N/R	N/R
2021	N/R	24	$960
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	78	78	$191
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	203	521	$152
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	70	79	$141
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	73	83	$108
J7050	Infusion, normal saline solution, 250 cc	42	119	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Sprycel	Dasatinib	13	390	$238,398
Revlimid	Lenalidomide	13	273	$161,586
Eliquis	Apixaban	80	2,928	$55,479
Anastrozole	Anastrozole	79	7,130	$1,251
Letrozole	Letrozole	14	1,200	$615

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$76	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rumaisa Hameed, M.D?

Tedicare shows public-source Medicare data for Rumaisa Hameed, M.D (NPI 1023447349), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rumaisa Hameed, M.D have ACO affiliation data?

Rumaisa Hameed, M.D is shown with ACO affiliation data for Sound Physicians Long Term Care Management, LLC (MSSP, ACO ID A5220).

What billing organization is linked to Rumaisa Hameed, M.D?

Rumaisa Hameed, M.D is linked to MEDSTAR MEDICAL GROUP II LLC (billing NPI 1184046187) in the available physician profile data.

Does Rumaisa Hameed, M.D have Open Payments data?

Rumaisa Hameed, M.D has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.